Japan's Shionogi, U.K.'s GSK Join For Resistant-Bacteria Drugs
This article was originally published in PharmAsia News
Executive Summary
Shionogi of Japan plans to join with U.K.-based GlaxoSmithKline to develop a new line of antibiotics capable of treating bacteria that have become drug-resistant